Infertility is a major late effect in patients receiving haematopoietic stem cell transplantation (HSCT). The aim of this study was to determine the proportion of patients having fertility impairment after allogeneic HSCT in childhood/adolescence and to identify the potential risk factors. Treatment and fertility data of paediatric patients with malignant and non-malignant diseases treated with allogeneic HSCT between 2000 and 2005 were collected from seven European centres. Data were obtained for 138 female and 206 male patients after a median follow-up of 6 years (range 3-12). The patients' median age was 13 years (range 4-28) at the time of years at the time of the enquiry. Seven children were born to the overall group, all at term and healthy. Fertility impairment was suspected in 69% males and 83% females. Start of treatment at age X13 years was a risk factor in females (odds ratio (OR) 4.7; 95% confidence interval (CI), 1.5 to 14.9), whereas pre-pubertal therapy was a risk factor in males (OR 0.4; 95% CI, 0.2 to 0.8). The major treatment-related risk factors were BU in females (OR 47.4; 95% CI, 5.4 to 418.1) and TBI in males (OR 7.7; 95% CI, 2.3 to 25.4). In light of the significant proportion of HSCT patients reviewed with impaired fertility, fertility conservation procedures should be considered for all patients undergoing HSCT, particularly those receiving TBI or BU-based preparative regimens.
Introduction
The numbers of long-term survivors following haematopoietic stem cell transplantation (HSCT) have been noticeably increasing in recent years. 1 Preparative regimens are associated with a high risk of infertility, and young patients wish to have an unrestricted quality of life as adults, including, in most cases, having children of their own. 2, 3 Studies have shown that the infertility induced by cytostatic drugs is dependent on type and dosage of the drug used, and also on the patients' age at the time of treatment. [4] [5] [6] [7] The most common conditioning regimen used are 12-14 Gy of TBI and CY (120 mg/kg) or etoposide (VP-16, 60 mg/kg) or a combination of BU (16 mg/kg) and CY (120 mg/kg). A number of small studies conducted with adults have shown that VP-16, BU and CY, along with other cytostatic drugs, can lead to fertility impairment, depending on the dose administered. 8, 9 Radiotherapy-induced gonadal damage is dose-and agedependent in both sexes. In men, doses above 4 Gy can lead to irreversible azoospermia. 2, 10 Because of the lower sensitivity of testosterone-producing Leydig cells, reduced testosterone values are only expected after a radiation dose of 20 Gy.
11 Potential for recovery with increasing periods of time since HSCT has been reported, 2 but if damage to the ovaries has occurred once, it is usually thought to be irreversible and can lead to infertility and amenorrhoea. 12 Even in pre-menarcheal girls, an ovarian dosage of 15 Gy can lead to irreversible fertility impairment. 13 Impaired fertility in females seems to be closely related to the destruction of oocytes, which also impairs sex steroid production. Ovarian biopsies performed in patients undergoing chemoradiotherapy showed ovarian damage accompanied by fibrosis, with no evidence of follicular maturation. [14] [15] [16] [17] Pregnancies do occur among patients who have undergone HSCT as children; however, they are rare. The aims of this study were to identify pregnancies and their outcomes as well as to determine fertility status and possible risk factors for infertility in former patients treated at seven European HSCT centres.
Patients and methods
In this retrospective study, data were collected from seven paediatric centres for HSCT in Germany (Berlin, Du¨ssel-dorf, Erlangen, Frankfurt, Muenster), Austria (Vienna) and the Czech Republic (Prague). Information was requested regarding fertility parameters and the course of pregnancies in former paediatric patients who had received allogeneic HSCT in the period 2000-2005. All patients were included if they were at least 12 years old at the time of the study in 2009. The fertility parameters used were taken from the patients' long-term follow-up data, such as spermiograms, testicular volume measurements, details of menstrual cycles and hormone substitution, as well as hormone analyses for luteinizing hormone (LH), folliclestimulating hormone (FSH), testosterone and oestrogen.
Patients were classified as having impaired fertility or a suspicion of hypergonadotropic hypogonadism at FSH 415 IU/L, LH415 IU/L, testosterone in males o2 ng/mL and oestradiol in women o30 pg/mL. In addition to abnormal hormone levels suspicious for hypergonadotropic hypogonadism, the following parameters were also included as criteria for 'suspected infertility': amenorrhoea, azoospermia, hormone replacement therapy and microorchidism, defined as a testicular volume of o12 mL. 18 For our analysis, based on patient records, we defined puberty status in two categories: 'Pre-puberty' for children aged up to 12 years and 'puberty' for children aged 13 years and older at the time of HSCT.
The data were analysed using the Statistical Package for the Social Sciences, version 17 (IBM Corporation, Somers, NY, USA). Mann-Whitney U tests (for continuous variables) and w 2 tests (for categorical variables) were conducted to test differences between groups (significance level Po0.05). Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable logistic regression analyses to estimate the impact of different chemotherapeutic agents and types of radiotherapy on fertility status.
Results
Out of 344 patients included, 60% were male. The distribution of diagnoses showed some gender-specific differences: acute lymphoblastic leukaemia and adrenoleukodystrophy were relatively more common, whereas chronic lymphoblastic leukaemia, myelodysplastic syndrome and severe aplastic anaemia were relatively less common in males compared with females. A conditioning regimen without TBI was more common in females than males: 61 versus 54% (Table 1) .
At a median of 6 years (range 3-12 years) after HSCT 22 of the 133 females (17%) and 59 of the 190 males with data on fertility (31%) seemed to be fertile. Analysing fertility separately for malignant and non-malignant diagnoses, we found that 21% of the patients with malignant and 42% of the patients with non-malignant diagnoses were presumed fertile. Five participants (three female and two male) were reported to have had babies, all born at term and healthy. None had received TBI. One female experienced amenorrhoea after the birth of her child ( Table 2) .
Females
Based on our criteria, 111 (83%) of the 133 females with data on fertility were classified as being infertile: 9 out of 38 women with information on their menstrual cycle had amenorrhoea, 68 were receiving hormone substitution and 42 of the women not taking hormone replacement therapy had abnormal values on hormone analysis (FSH415 IU/L, n ¼ 26; LH415 IU/l, n ¼ 21; oestradiol o30 pg/mL, n ¼ 31). In 10 of the 111 patients classified as infertile, hormone substitution was the only criterion for suspected infertility. It is possible that some of these 10 women only used hormone substitution for contraceptive reasons meaning that the infertility rate may be lower than 83%.
Females aged 1-12 years at the time of HSCT had lower medians of LH and FSH, which were both within the normal range (o15 IU/L), compared with those aged 13 or older at the time of HSCT (Table 3 ). Comparing the two age groups, suspected infertility was present in 38 of 53 (72%) participants treated at ages 1-12, compared with 73 (91%) of 80 who were treated at age 13 or later (P ¼ 0.003).
Fifty-four females received TBI with a median of 12.0 Gy (range 2.0-14.4 Gy) Slightly more of the females who underwent TBI had signs of suspected infertility (46 of 52, 89%) compared with those without TBI (65 of 81, 80%), but this difference was not statistically significant.
Four females received TLI, elevated gonadotropin levels were seen in one patient. Table 4 gives an overview of seven female patients who had received non-myeloablative therapy.
In the group of females, BU (administered at a median dosage of 15 mg/kg; range 2.0-17.8) compared with females who did not receive BU, represented a significant risk factor for infertility in comparison with the other chemotherapeutic agents. In the group of female participants treated with BU, both median LH and median FSH values were significantly higher than in those not receiving BU treatment (Table 3 ). There were also significantly more female participants with suspected infertility after BU therapy (50 of 51, 98%) than not after BU therapy (61 of 82, 74%, Po0.001).
In multivariable logistic regression analyses, puberty compared with pre-puberty (OR 4.7; 95% CI, 1.5 to 14.9), TBI versus no TBI (OR 4.9; 95% CI, 1.2 to 19.9;) and BU versus no BU (OR 47.4; 95% CI, 5.4 to 418.1) significantly increased the risk of infertility. No association with infertility was found for CY and VP-16.
Males
A total of 131 of the 190 males (69%) with data on fertility were considered to be infertile based on one or more criteria for impaired fertility: azoospermia (n ¼ 7), hormone replacement therapy (n ¼ 10), hormonal analysis (n ¼ 101; FSH 415 IU/L, n ¼ 66; LH415 IU/L, n ¼ 16; testosterone o2 ng/mL, n ¼ 38). Testicular volumes were measured in 99 male participants by the local centre conducting the treatment. Microorchidism was seen in 50 of these patients. Analyses of testicular volume showed no statistically significant correlations with FSH (r ¼ À0.118) or LH Males aged 1-12 years at the time of HSCT had significant lower medians of LH and of FSH, which were both within the normal ranges, compared with males aged 13 years or older at HSCT (Table 3) . Comparing the age groups we found-in contrast to the female participantsthat suspected infertility was less frequent in males who received HSCT treatment at the age of 13 or later (60 of 100, 60%) than in those in whom treatment started at the ages of 1-12 (71 of 90, 79%).
In all, 95 males received TBI at a median dose of 12.3 Gy (range 2.0-14.4 Gy). Male participants who received TBI had significantly higher FSH values than those not receiving TBI (Po0.001). LH values were also raised in the group of TBI patients (P ¼ 0.04; Table 3 ). Suspected infertility was significantly more frequent among male participants who underwent TBI (76 of 91, 84%) than among those not receiving TBI (55 of 99, 56%; Po0.001).
Three males received TLI of 2 Gy, 5 Gy and 5 Gy. Hypergonadotropic hypogonadism was present in one participant in this group. Table 4 gives an overview on 12 male patients with non-myeloablative therapy.
BU was given at a median dose of 16 mg/kg (range 2-20 mg/kg). In the group of male participants treated with BU, the median LH was lower compared with those without BU, but the difference was not statistically significant. FSH values were significantly higher in the participants who did not receive BU treatment. There were fewer participants with suspected infertility among male patients who received BU therapy (43 of 69, 62%) than among patients who did not (88 of 121, 73%; P ¼ 0.136).
In multivariable logistic regression analyses, TBI compared with no TBI (OR 7.7; 95% CI, 2.3 to 25.4) and Table 4 Hormone analysis in patients with non-myeloablative conditioning regime (TBI/TLIo6 Gy or BU 2 mg/kg) Fertility after HSCT in childhood and adolescence A Borgmann et al pre-puberty compared with puberty (OR 0.4; 95% CI, 0.2 to 0.8) were found to significantly increase the risk of infertility. BU, CY and VP16 were not associated with infertility in male subjects.
Discussion
The present study on the topic-the largest such investigation conducted to date in paediatric HSCT recipientsincluded data on treatment and fertility from 344 patients from seven paediatric HSCT centres in Europe. After a median follow-up period of 6 years from HSCT, the infertility rate in the study group was 75% overall, with rates of 83% in the female participants and 69% in the male participants. The follow-up period of 6 years after the start of treatment does not seem to be too short, in view of the fact that testicular recovery occurs in the initial years after HSCT and that the sharpest decline in ovarian reserve takes place immediately after treatment. 19, 20 Seven children were born to the overall group, all at term and healthy. None of the female participants who became pregnant or male patients who fathered a child had been treated with TBI before HSCT. Pregnancies after HSCT have to date been regarded as a rarity. If a woman became pregnant, however, it has been recommended that she should receive close monitoring, as higher rates of miscarriage and premature birth have been reported. Congenital abnormalities have not been found to occur more frequently in these cases. 3 Impaired fertility is a well-known side effect after HSCT in childhood and adolescence but studies in the field are often limited by small numbers of patients in the various groups. [21] [22] [23] A recent study on the recovery of spermatogenesis after HSCT reported that spermatozoa were found in sperm fluid analyses in 58 of 217 males (27%) after a median follow-up period of 4.5 years. 24 A recent review of paediatric HSCT reported that impaired fertility was present in nearly all females treated with conditioning protocols including BU. CY-induced ovarian failure was also reported in female survivors after HSCT, although to a lesser extent. 2 Examining risk factors for infertility in the present study, TBI in particular appeared to be gonadotoxic for males. Male participants who underwent TBI had significantly higher FSH values and showed signs of suspected infertility more often. The discrepancy between the abnormal FSH values and the testosterone values, which were less often abnormal by comparison, may be explained by the lower sensitivity of Leydig cells. This is consistent with the finding that most boys undergo normal pubertal development after HSCT, with the exception of testicular size. 2 It was not possible to investigate the recently reported risk factor of a graft-versus-testis effect on the basis of the available data in the present study. 24 The major treatment-related risk factor among females in our study was BU treatment. When examining the FSH and LH values for female participants in relation to age at treatment, we found that starting treatment after the age of 13 years significantly increased the risk for infertility. In males, however, pre-pubertal therapy was found to increase the risk for infertility, which is inconsistent with findings of other recent studies. 21 The fact that TBI was a significant risk factor for infertility in males is not surprising given that impaired sperm production in the form of temporary oligospermia occurs after radiotherapy at dosages as low as 0.1 Gy. This azoospermia may resolve over a period of years. Doses of 1.5 Gy or more can lead to long-term cessation of sperm production and doses above 4 Gy to irreversible azoospermia. 10 Ovarian damage occurred after a TBI dose of 12 Gy in girls over the age of 10 years in virtually all cases, whereas in girls o10 years only in approximately a half. 2 
Conclusion
More than two-third of former paediatric patients who had received allogeneic HSCT showed signs of impaired fertility. Significant risk factors were TBI for males and BU for females. Our results emphasise the need for comprehensive counselling of patients undergoing HSCT, particularly those receiving TBI-or busulfan based preparative regimens and their parents regarding fertility preserving measures.
